53 results on '"Critchley, Hilary O. D."'
Search Results
2. The impact of meridian balance method electro-acupuncture treatment on chronic pelvic pain in women: a three-armed randomised controlled feasibility study using a mixed-methods approach.
- Author
-
Chong, Ooi Thye, Critchley, Hilary O. D., Williams, Linda J., Haraldsdottir, Erna, Horne, Andrew W., and Fallon, Marie
- Subjects
- *
PELVIC pain treatment , *WOMEN , *WOMEN'S health , *ELECTROACUPUNCTURE , *RANDOMIZED controlled trials - Abstract
Introduction: Chronic pelvic pain (CPP) is estimated to affect 6%–27% of women worldwide. In the United Kingdom, over 1 million women suffer from CPP and it has been highlighted as a key area of unmet need. Standard treatments are associated with unacceptable side effects. The meridian balance method electro-acupuncture (BMEA), and traditional Chinese medicine health consultation (TCM HC) (BMEA + TCM HC = BMEA treatment) may be an effective adjunct to standard treatment. Aim: The aim of our study was to evaluate the feasibility of a future trial, to determine the effectiveness of the BMEA treatment for CPP in women. The primary objectives were to determine recruitment and retention rates. The secondary objectives were to assess the effectiveness of the BMEA treatment and acceptability of the study’s methodology. Methods: Women with CPP were randomised into BMEA treatment (group 1), TCM HC alone (group 2) (each intervention administered twice weekly for 4 weeks) or National Health Service standard care (NHS SC, group 3). Primary outcomes were assessed by the proportion of eligible participants randomised, and the proportion of randomised participants who returned follow-up questionnaires. Interventions were assessed by validated pain/physical/emotional functioning questionnaires at baseline (0), 4, 8 and 12 weeks. Focus groups and semi-structured telephone interviews were embedded in the study. Results: A total of 30 women (51% of those referred) were randomised over 8 months. Retention rates were 80% (95% confidence interval (CI): 74–96), 53% (95% CI: 36–70) and 87% (95% CI: 63–90), in groups 1, 2, and 3, respectively. Qualitative data suggested a favourable trial experience in groups 1 and 3. Discussion: Group 2 retention rate was problematic and has implications for our next trial. Conclusion: Our study suggests that a future trial to determine the effectiveness of BMEA treatment for women with CPP is feasible but with modifications to the study design. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
3. Contemporary evaluation of women and girls with abnormal uterine bleeding: FIGO Systems 1 and 2.
- Author
-
Jain, Varsha, Munro, Malcolm G., and Critchley, Hilary O. D.
- Subjects
- *
UTERINE hemorrhage , *IRON deficiency anemia , *METRORRHAGIA , *MENORRHAGIA , *GIRLS , *CHILDBEARING age , *DISEASE complications - Abstract
Abnormal uterine bleeding (AUB) is common, often debilitating, and may affect over 50% of reproductive‐aged women and girls. Whereas AUB is a collection of symptoms that include intermenstrual bleeding and abnormalities in period duration, cycle length, and regularity, it is heavy menstrual bleeding (HMB) that is most contributory to iron deficiency and related anemia. It is apparent that AUB, in general, and HMB, in particular, remain underrecognized and underreported. FIGO created two systems for assessing and classifying AUB. FIGO System 1 defines the bleeding pattern using four primary descriptors: frequency, duration, regularity, and flow volume. FIGO System 2 provides a structured classification system of possible causes of AUB, using the acronym PALM‐COEIN. "PALM" refers to structural causes of AUB (Polyp, Adenomyosis, Leiomyoma, Malignancy), and "COEI" refers to nonstructural causes (Coagulopathy, Ovulatory dysfunction, Endometrial, and Iatrogenic). The "N" is reserved for those entities that are currently not otherwise classified. Using FIGO System 1 as a gateway to FIGO System 2 streamlines the investigation of reproductive‐aged women and girls with AUB. Understanding the pathogenesis of the FIGO System 2 "PALM‐COEIN" causes helps interpret investigations and the onward management of AUB. Numerous evidence gaps exist concerning AUB; however, if researchers and trialists universally adopt FIGO Systems 1 and 2 for the assessment and diagnosis of AUB, clear translatable research findings can be applied globally. Synopsis: Abnormal uterine bleeding and its associated conditions (iron deficiency with/without anemia) are underrecognized and underreported, requiring precise, systematic assessment using FIGO systems 1 and 2. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. New concepts for an old problem: the diagnosis of endometrial hyperplasia.
- Author
-
Sanderson, Peter A., Critchley, Hilary O. D., Williams, Alistair R. W., Arends, Mark J., and Saunders, Philippa T. K.
- Subjects
- *
ENDOMETRIAL hyperplasia , *ENDOMETRIAL cancer risk factors , *CANCER invasiveness , *BIOMARKERS ,CANCER histopathology - Abstract
Background: Endometrial hyperplasia (EH) is a uterine pathology representing a spectrum of morphological endometrial alterations. It is predominantly characterized by an increase in the endometrial gland-to-stroma ratio when compared to normal proliferative endometrium. The clinical significance of EH lies in the associated risk of progression to endometrioid endometrial cancer (EC) and 'atypical' forms of EH are regarded as premalignant lesions. Traditional histopathological classification systems for EH exhibit wide and varying degrees of diagnostic reproducibility and, as a consequence, standardized patient management can be challenging.Objective and Rationale: EC is the most common gynaecological malignancy in developed countries. The incidence of EC is rising, with alarming increases described in the 40-44-year-old age group. This review appraises the current EH classification systems used to stratify women at risk of malignant progression to EC. In addition, we summarize the evidence base regarding the use of immunohistochemical biomarkers for EH and discuss an emerging role for genomic analysis.Search Methods: PubMed, Medline and the Cochrane Database were searched for original peer-reviewed primary and review articles, from January 2000 to January 2016. The following search terms were used: 'endometrial hyperplasia', 'endometrial intraepithelial neoplasia', 'atypical hyperplasia', 'complex atypical hyperplasia', 'biomarker', 'immunohistochemistry', 'progression', 'genomic', 'classification' and 'stratification'.Outcomes: Recent changes to EH classification reflect our current understanding of the genesis of endometrioid ECs. The concept of endometrial intraepithelial neoplasia (EIN) as a mutationally activated, monoclonal pre-malignancy represents a fundamental shift from the previously held notion that unopposed oestrogenic stimulation causes ever-increasing hyperplastic proliferation, with accumulating cytological atypia that imperceptibly leads to the development of endometrioid EC. Our review highlights several key biomarker candidates that have been described as both diagnostic tools for EH and markers of progression to EC. We propose that, moving forwards, a 'panel' approach of combinations of the immunohistochemical biomarkers described in this review may be more informative since no single candidate can currently fill the entire role.Wider Implications: EC has historically been considered a predominantly postmenopausal disease. Owing in part to the current unprecedented rates of obesity, we are starting to see signs of a shift towards a rising incidence of EC amongst pre- and peri-menopausal woman. This creates unique challenges both diagnostically and therapeutically. Furthering our understanding of the premalignant stages of EC development will allow us to pursue earlier diagnosis and facilitate appropriate stratification of women at risk of developing EC, permitting timely and appropriate therapeutic interventions. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
5. Menstrual physiology: implications for endometrial pathology and beyond.
- Author
-
Maybin, Jacqueline A. and Critchley, Hilary O. D.
- Subjects
- *
MENSTRUAL cycle , *ENDOMETRIAL diseases , *MENSTRUATION , *FERTILIZATION (Biology) , *EMBRYO implantation , *NEOVASCULARIZATION , *ENDOMETRIUM physiology , *ENDOMETRIUM , *INFLAMMATION , *REGENERATION (Biology) , *RESEARCH funding , *FETAL development - Abstract
Background: Each month the endometrium becomes inflamed, and the luminal portion is shed during menstruation. The subsequent repair is remarkable, allowing implantation to occur if fertilization takes place. Aberrations in menstrual physiology can lead to common gynaecological conditions, such as heavy or prolonged bleeding. Increased knowledge of the processes involved in menstrual physiology may also have translational benefits at other tissue sites.Methods: Pubmed and Cochrane databases were searched for all original and review articles published in English until April 2015. Search terms included 'endometrium', 'menstruation', 'endometrial repair', 'endometrial regeneration' 'angiogenesis', 'inflammation' and 'heavy menstrual bleeding' or 'menorrhagia'.Results: Menstruation occurs naturally in very few species. Human menstruation is thought to occur as a consequence of preimplantation decidualization, conferring embryo selectivity and the ability to adapt to optimize function. We highlight how current and future study of endometrial inflammation, vascular changes and repair/regeneration will allow us to identify new therapeutic targets for common gynaecological disorders. In addition, we describe how increased knowledge of this endometrial physiology will have many translational applications at other tissue sites. We highlight the clinical applications of what we know, the key questions that remain and the scientific and medical possibilities for the future.Conclusions: The study of menstruation, in both normal and abnormal scenarios, is essential for the production of novel, acceptable medical treatments for common gynaecological complaints. Furthermore, collaboration and communication with specialists in other fields could significantly advance the therapeutic potential of this dynamic tissue. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
6. IL1α and IL4 signalling in human ovarian surface epithelial cells.
- Author
-
Papacleovoulou, Georgia, Critchley, Hilary O. D., Hillier, Stephen G., and Mason, J. Ian
- Subjects
- *
INTERLEUKIN-1 , *INTERLEUKIN-4 , *EPITHELIAL cells , *OVULATION , *INFLAMMATION , *PROGESTERONE , *CELLULAR signal transduction , *MESSENGER RNA - Abstract
The human ovarian surface epithelium (hOSE) is a mesothelial layer that surrounds the ovary and undergoes injury and repair cycles after ovulation-associated inflammation. We previously showed that IL4 is a key regulator of progesterone bioavailability during post-ovulatory hOSE repair as it differentially up-regulated 3β-HSD1 and 3β-HSD2 mRNA transcripts and total 3β-hydroxysteroid dehydrogenase activity whereas it inhibited androgen receptor (AR) expression. We now show that the pro-inflammatory effect of IL1α on 3β-HSD1 expression is mediated by nuclear factor-κB (NF-κB), whereas its anti-inflammatory action on 3β-HSD2 expression is exerted via p38 mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K) and NF-κB signalling pathways. The anti-inflammatory IL4 effects on 3β-HSD1 and 3β-HSD2 mRNA expression are mediated through STAT6 and PI3K signalling networks. IL4 effects on AR and 3b-HSD2 expression involve the p38 MAPK pathway. We also document that IL4 up-regulates lysyl oxidase (LOX) mRNA transcripts, a key gene for extracellular matrix (ECM) deposition and inhibits IL1a-induced expression of cyclooxygenase-2 (COX-2) mRNA, a gene involved in breakdown of ECM, showing a further role in post-ovulatory wound healing. We conclude that IL1a and IL4 actions in the post-ovulatory wound healing of hOSE cells are mediated by different signalling transduction pathways. The p38 MAPK signalling pathway may have possible therapeutic benefit in inflammation-associated disorders of the ovary, including cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
7. La clasificación FIGO de causas de sangrado uterino anormal en los años reproductivos.
- Author
-
Munro, Malcolm G., Critchley, Hilary O. D., and Fraser, Ian S.
- Subjects
- *
UTERUS abnormalities , *CLASSIFICATION , *GYNECOLOGY , *POLYPS , *UTERINE fibroids , *HYPERPLASIA , *IATROGENIC diseases , *MEDICAL societies ,DIAGNOSIS of uterine diseases - Abstract
At this juncture, clinical management, education for medical providers, and the design and interpretation of clinical trials have been hampered by the absence of a consensus system for nomenclature for the description of symptoms as well as classification of causes or potential causes of abnormal uterine bleeding (AUB). To address this issue, the Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) has designed the PALM-COEIN (Polyp, Adenomyosis, Leiomyoma, Malignancy and Hyperplasia, Coagulopathy, Ovulatory Disorders, Endometrial Disorders, Iatrogenic Causes, and Not Classified) classification system for causes of AUB in the reproductive years [ABSTRACT FROM AUTHOR]
- Published
- 2011
8. Hormone Receptor Dynamics in a Receptive Human Endometrium.
- Author
-
Critchley, Hilary O. D. and Saunders, Philippa T. K.
- Subjects
- *
HORMONE receptors , *ENDOMETRIUM physiology , *LIGAND binding (Biochemistry) , *STEROID hormones , *PROGESTERONE , *HUMAN fertility - Abstract
The text herein is an overview of hormone receptor dynamics in human endometrium as presented at the Society for Gynecologic Investigation Summit on Implantation. It is not an in-depth review. Endometrial function is modulated by circulating steroids that bind ligand-activated receptors and initiate a cascade of molecular and cellular events. Cell-specific targets for steroid hormone action have been defined using immunohistochemistry. Local ligand availability is modulated by steroid metabolizing enzymes expressed within endometrial tissue. Insight on impact of progestogens on endometrial function has derived from studies of pharmacological withdrawal using progesterone receptor antagonists. Microarray analysis of human endometrium, studies in mouse models and in vitro have documented gene expression changes regulated by progesterone and implicated this hormone in determining uterine receptivity. Understanding of the impact of local and peripheral steroids on endometrial function is important for fertility control and for understanding how disturbances of endometrial structure and function play a role in subfertility. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
9. Regulation of human endometrial function: mechanisms relevant to uterine bleeding.
- Author
-
Critchley, Hilary O. D., Kelly, Rodney W., Baird, David T., and Brenner, Robert M.
- Subjects
- *
ENDOMETRIUM , *UTERINE hemorrhage , *MENSTRUATION , *PROGESTERONE , *ORAL contraceptives , *BIRTH control - Abstract
This review focuses on the complex events that occur in the endometrium after progesterone is withdrawn (or blocked) and menstrual bleeding ensues. A detailed understanding of these local mechanisms will enhance our knowledge of disturbed endometrial/uterine function — including problems with excessively heavy menstrual bleeding, endometriosis and breakthrough bleeding with progestin only contraception. The development of novel strategies to manage these clinically significant problems depends on such new understanding as does the development of new contraceptives which avoid the endometrial side effect of breakthrough bleeding. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
10. The acceptability of home medical abortion to women in UK settings.
- Author
-
Hamoda, Haitham, Critchley, Hilary O. D., Paterson, Kate, Guthrie, Kate, Rodger, Mary, and Penney, Gillian C.
- Subjects
- *
ABORTION , *OBSTETRICS surgery , *PREGNANCY , *WOMEN'S health services - Abstract
To assess the acceptability of home medical abortion to women in UK settings.Questionnaire survey.Four NHS gynaecology units in England and Scotland.Women undergoing conventional, hospital-based, medical abortion up to nine weeks of gestation.A self-complete questionnaire explored the acceptability of abortion in hospital (including pain and bleeding experienced) and at home. Comparisons were made between centres (English and Scottish).Women's views on home administration of misoprostol for medical abortion; perceived acceptability and perceived ability to cope with the process at home.Sixty-six percent (366/553) of the questionnaires were returned: Edinburgh, 204 (56%); London, 92 (25%); Hull, 43 (12%); and Glasgow, 27 (7%). Individual questionnaire items were answered by varying numbers of women: 228/320 (71%; 95% CI: 66–76%) said there was nothing that happened during abortion in the hospital that they would have been unable to cope with at home; 123/342 (36%; 95% CI: 31–41%) said they would have opted to have home abortion, had that choice been available. However, 219/342 (64%; 95% CI: 59–69%) indicated that they would prefer to have abortion in the hospital. The majority of women said they would have coped at home with bleeding (280/355, 79%; 95% CI: 74–83%) and with pain if given analgesia (203/268, 76%; 95% CI: 70–81%).This study suggests that most women would welcome being offered the choice of having medical abortion at home or in hospital. The development of home abortion must be seen as complementary, not an alternative, to hospital services. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
11. Innate immune defences in the human endometrium.
- Author
-
King, Anne E., Critchley, Hilary O. D., and Kelly, Rodney W.
- Subjects
- *
ENDOMETRIUM , *PATHOGENIC microorganisms , *IMMUNE system , *REPRODUCTIVE health , *HUMAN behavioral endocrinology , *ENDOCRINOLOGY , *BIOLOGY - Abstract
The human endometrium is an important site of innate immune defence, giving protection against uterine infection. Such protection is critical to successful implantation and pregnancy. Infection is a major cause of preterm birth and can also cause infertility and ectopic pregnancy. Natural antimicrobial peptides are key mediators of the innate immune system. These peptides, between them, have anti-bacterial, anti-fungal and anti-viral activity and are expressed at epithelial surfaces throughout the female genital tract. Two families of natural anti-microbials, the defensins and the whey acidic protein (WAP) motif proteins, appear to be prominent in endometrium. The human endometrial epithelium expresses beta-defensins 1-4 and the WAP motif protein, secretory leukocyte protease inhibitor. Each beta-defensin has a different expression profile in relation to the stage of the menstrual cycle, providing potential protection throughout the cycle. Secretory leukocyte protease inhibitor is expressed during the secretory phase of the cycle and has a range of possible roles including anti-protease and anti-microbial activity as well as having effects on epithelial cell growth. The leukocyte populations in the endometrium are also a source of antimicrobial production. Neutrophils are a particularly rich source of alpha-defensins, lactoferrin, lysozyme and the WAP motif protein, elafin. The presence of neutrophils during menstruation will enhance anti-microbial protection at a time when the epithelial barrier is disrupted. Several other anti-microbials including the natural killer cell product, granulysin, are likely to have a role in endometrium. The sequential production of natural anti-microbial peptides by the endometrium throughout the menstrual cycle and at other sites in the female genital tract will offer protection from many pathogens, including those that are sexually transmitted. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
12. The endocrinology of menstruation – a role for the immune system.
- Author
-
Critchley, Hilary O. D., Kelly, Rodney W., Brenner, Robert M., and Baird, David T.
- Subjects
- *
MENSTRUATION , *ENDOCRINOLOGY - Abstract
Examines the endocrinology of menstruation. Manifestation of cyclical ovarian function; Role of leucocyte in the menstrual breakdown process; Effects of vasoconstriction and hypoxia on the menstrual cycle; Effect of progesterone withdrawal on cells with progesterone receptors.
- Published
- 2001
- Full Text
- View/download PDF
13. Choice of hormone replacement therapy in young women with ovarian failure.
- Author
-
Bath, Louise E., Critchley, Hilary O. D., Kelnar, Christopher J. H., and Wallace, W. Hamish B.
- Subjects
- *
HORMONE therapy , *HUMAN abnormalities , *ESTROGEN , *OVARIES - Abstract
Focuses on the choice of hormone replacement therapy in young women with ovarian failure. Consensus on the optimum estrogen and progesterone replacement; Influence of choice on patient's convenience and acceptability; Aim of achieving optimum skeletal and cardiovascular health.
- Published
- 2001
- Full Text
- View/download PDF
14. Referral for menstrual problems: cross sectional survey of symptoms, reasons for referral, and management.
- Author
-
Warner, Pamela, Critchley, Hilary O D, Lumsden, Mary Ann, Campbell-Brown, Mary, Douglas, Anne, and Murray, Gordon
- Subjects
- *
MENSTRUATION disorders , *MENORRHAGIA , *WOMEN'S health , *WOMEN'S health services - Abstract
Conclusions: Intolerance of the volume of their bleeding is not a key feature among women attending clinics for bleeding problems. Broad menstrual complaint tends to be reframed as excessive bleeding at referral and during management. This may result in women receiving inappropriate care. Conceptualisation and assessment of menorrhagia requires reconsideration. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
15. Menstruation should not be overlooked in control of anaemia.
- Author
-
Critchley, Hilary O. D., Munro, Malcolm G., Shakur-Still, Haleema, and Roberts, Ian
- Published
- 2021
- Full Text
- View/download PDF
16. Menstruation should not be overlooked in control of anaemia.
- Author
-
Critchley, Hilary O D, Munro, Malcolm G, Shakur-Still, Haleema, and Roberts, Ian
- Subjects
- *
MENSTRUATION , *ANEMIA , *ANEMIA treatment , *WORLD health , *NUTRITIONAL status - Published
- 2021
- Full Text
- View/download PDF
17. Standardising outcome reporting for clinical trials of interventions for heavy menstrual bleeding: Development of a core outcome set.
- Author
-
Cooper, Natalie A. M., Rivas, Carol, Munro, Malcolm G., Critchley, Hilary O. D., Clark, T. Justin, Matteson, Kristen A., Papadantonaki, Rosa, Yorke, Sarah, Tan, Alex, Bofill Rodriguez, Magdalena, Bongers, Marlies, Al‐Hendy, Ayman, Bahamondes, Luis, Connolly, Anne, Farquhar, Cindy, Gray Valbrun, Tanika, Hickey, Martha, Taylor, Hugh S., Toub, David, and Vannuccini, Silvia
- Subjects
- *
LIFE change events , *MENORRHAGIA , *PATIENT satisfaction , *MENSTRUAL cycle , *DYSMENORRHEA , *FLOOD damage , *UTERINE hemorrhage - Abstract
Objective: To develop a core outcome set for heavy menstrual bleeding (HMB). Design: Core outcome set (COS) development methodology described by the COMET initiative. Setting: University hospital gynaecology department, online international survey and web‐based international consensus meetings. Population or sample: An international collaboration of stakeholders (clinicians, patients, academics, guideline developers) from 20 countries and 6 continents. Methods: Phase 1: Systematic review of previously reported outcomes to identify potential core outcomes. Phase 2: Qualitative studies with patients to identify outcomes most important to them. Phase 3: Online two‐round Delphi survey to achieve consensus about which outcomes are most important. Phase 4: A consensus meeting to finalise the COS. Main outcome measures: Outcome importance was assessed in the Delphi survey on a 9‐point scale. Results: From the 'long list' of 114, 10 outcomes were included in the final COS: subjective blood loss; flooding; menstrual cycle metrics; severity of dysmenorrhoea; number of days with dysmenorrhoea; quality of life; adverse events; patient satisfaction; number of patients going on to have further treatment for HMB and haemoglobin level. Conclusions: The final COS includes variables that are feasible for use in clinical trials in all resource settings and apply to all known underlying causes of the symptom of HMB. These outcomes should be reported in all future trials of interventions, their systematic reviews, and clinical guidelines to underpin policy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Outcomes From Leiomyoma Therapies: Comparison With Normal Controls.
- Author
-
Munro, Malcolm G., Critchley, Hilary O. D., Fraser, Jan S., and Spies, James B.
- Subjects
- *
LETTERS to the editor , *SMOOTH muscle tumors , *HYSTERECTOMY , *TUMOR treatment - Abstract
A letter to the editor is presented in response to the article "Outcomes from leiomyoma therapies: comparison with normal controls," by J. B. Spies, L. D. Bradley, R. Guido, G. L. Maxwell, B. A. Levine and K. Coyne.
- Published
- 2011
- Full Text
- View/download PDF
19. The FIGO ovulatory disorders classification system.
- Author
-
Munro, Malcolm G., Balen, Adam H., Cho, SiHyun, Critchley, Hilary O. D., Díaz, Ivonne, Ferriani, Rui, Henry, Laurie, Mocanu, Edgar, van der Spuy, Zephne M., and FIGO Committee on Menstrual Disorders and Related Health Impacts, and FIGO Committee on Reproductive Medicine, Endocrinology, and Infertility
- Subjects
- *
POLYCYSTIC ovary syndrome treatment , *POLYCYSTIC ovary syndrome , *UTERINE diseases , *GYNECOLOGY - Abstract
Ovulatory disorders are common causes of amenorrhea, abnormal uterine bleeding, and infertility, and are frequent manifestations of polycystic ovary syndrome (PCOS). There are many potential causes and contributors to ovulatory dysfunction that challenge clinicians, trainees, educators, and those who perform basic, translational, clinical, and epidemiological research. Similarly, therapeutic approaches to ovulatory dysfunction potentially involve a spectrum of lifestyle, psychological, medical, and procedural interventions. Collaborative research, effective education, and consistent clinical care remain challenged by the absence of a consensus comprehensive system for classification of these disorders. The existing and complex system, attributed to WHO, was developed more than three decades ago and did not consider more than 30 years of research into these disorders in addition to technical advances in imaging and endocrinology. This manuscript describes the development of a new classification of ovulatory disorders performed under the aegis of the International Federation of Gynecology and Obstetrics (FIGO) and conducted using a rigorously applied Delphi process. The stakeholder organizations and individuals who participated in this process comprised specialty journals, experts at large, national, specialty obstetrical and gynecological societies, and informed lay representatives. After two face-to-face meetings and five Delphi rounds, the result is a three-level multi-tiered system. The system is applied after a preliminary assessment identifies the presence of an ovulatory disorder. The primary level of the system is based on an anatomic model (Hypothalamus, Pituitary, Ovary) that is completed with a separate category for PCOS. This core component of the system is easily remembered using the acronym HyPO-P. Each anatomic category is stratified in the second layer of the system to provide granularity for investigators, clinicians, and trainees using the "GAIN-FIT-PIE" mnemonic (Genetic, Autoimmune, Iatrogenic, Neoplasm; Functional, Infectious and Inflammatory, Trauma and Vascular; Physiological, Idiopathic, Endocrine). The tertiary level allows for specific diagnostic entities. It is anticipated that, if widely adopted, this system will facilitate education, clinical care, and the design and interpretation of research in a fashion that better informs progress in this field. Integral to the deployment of this system is a periodic process of reevaluation and appropriate revision, reflecting an improved understanding of this collection of disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. PREGNANCY AND THE SARS-COV-2 PANDEMIC.
- Author
-
Reynolds, Rebecca M., Stock, Sarah J., Denison, Fiona C., Maybin, Jacqueline A., and Critchley, Hilary O. D.
- Subjects
- *
COVID-19 pandemic , *FETAL anoxia , *PREGNANCY , *PREGNANCY complications , *MEDICAL personnel , *ENDOTHELIUM diseases , *COVID-19 - Published
- 2022
- Full Text
- View/download PDF
21. Uterine bleeding: how understanding endometrial physiology underpins menstrual health.
- Author
-
Jain, Varsha, Chodankar, Rohan R., Maybin, Jacqueline A., and Critchley, Hilary O. D.
- Subjects
- *
UTERINE hemorrhage , *IRON deficiency anemia , *PHYSIOLOGY , *MENORRHAGIA , *MENSTRUAL cycle , *IRON deficiency , *ENDOMETRIUM physiology , *MENSTRUATION , *UTERINE diseases , *RESEARCH funding - Abstract
Menstruation is a physiological process that is typically uncomplicated. However, up to one third of women globally will be affected by abnormal uterine bleeding (AUB) at some point in their reproductive years. Menstruation (that is, endometrial shedding) is a fine balance between proliferation, decidualization, inflammation, hypoxia, apoptosis, haemostasis, vasoconstriction and, finally, repair and regeneration. An imbalance in any one of these processes can lead to the abnormal endometrial phenotype of AUB. Poor menstrual health has a negative impact on a person's physical, mental, social, emotional and financial well-being. On a global scale, iron deficiency and iron deficiency anaemia are closely linked with AUB, and are often under-reported and under-recognized. The International Federation of Gynecology and Obstetrics have produced standardized terminology and a classification system for the causes of AUB. This standardization will facilitate future research endeavours, diagnosis and clinical management. In a field where no new medications have been developed for over 20 years, emerging technologies are paving the way for a deeper understanding of the biology of the endometrium in health and disease, as well as opening up novel diagnostic and management avenues. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. <atl>Late effects of the treatment of childhood cancer on the female reproductive system and the potential for fertility preservation
- Author
-
Bath, Louise E., Wallace, W. Hamish B., and Critchley, Hilary O. D.
- Published
- 2002
- Full Text
- View/download PDF
23. Obesity is associated with heavy menstruation that may be due to delayed endometrial repair.
- Author
-
Reavey, Jane J., Walker, Catherine, Murray, Alison A., Brito-Mutunayagam, Savita, Sweeney, Sheona, Nicol, Moira, Cambursano, Ana, Critchley, Hilary O. D., and Maybin, Jacqueline A.
- Subjects
- *
MENSTRUATION , *OBESITY in women , *HIGH-fat diet , *MENORRHAGIA , *ENDOMETRIUM , *ETIOLOGY of diseases , *CONTRACEPTIVE drugs - Abstract
Heavy menstrual bleeding is common and debilitating but the causes remain ill defined. Rates of obesity in women are increasing and its impact on menstrual blood loss (MBL) is unknown. Therefore, we quantified BMI and MBL in w omen not taking hormones and with regular menstrual cycles and revealed a posit ive correlation. In a mouse model of simulated menstruation, diet-induced obesity also resulted in delayed endometrial repair, a surrogate marker for MBL. BrdU staining of mouse uterine tissue revealed decreased proliferation during menstruation in the luminal epithelium of mice on a high-fat diet. Menstruation is known to initiate local end ometrial inflammation and endometrial hypoxia; hence, the impact of body weight on these processes was investigated. A panel of hypoxia-regulated genes (VEGF, ADM, LDHA, SLC2A1) showed consistently higher mean values in the endometrium of women wit h obesity and in uteri of mice with increased weight vs normal controls, although stat istical significance was not reached. The inflammatory mediators, Tnf and Il6 were significantly increased in the uterus of mice on a high-fat diet, consistent with a pro-inflamm atory local endometrial environment in these mice. In conclusion, obesity was associate d with increased MBL in women. Mice given a high-fat diet had delayed endometrial repai r at menstruation and provided a model in which to study the influence of obesity on m enstrual physiology. Our results indicate that obesity results in a more pro-inflamma tory local endometrial environment at menstruation, which may delay endometrial repair and increase menstrual blood loss. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
- Author
-
Al-Hendy, Ayman, Lukes, Andrea S., Poindexter III, Alfred N., Venturella, Roberta, Villarroel, Claudio, Critchley, Hilary O. D., Yulan Li, McKain, Laura, Ferreira, Juan C. Arjona, Langenberg, Andria G. M., Wagman, Rachel B., Stewart, Elizabeth A., Poindexter, Alfred N 3rd, Li, Yulan, and Arjona Ferreira, Juan C
- Subjects
- *
ENDOMETRIAL hyperplasia , *FOOT pain , *TRANSVAGINAL ultrasonography , *BONE density , *RESEARCH , *UREA , *COMBINATION drug therapy , *CLINICAL trials , *HETEROCYCLIC compounds , *ESTRADIOL , *UTERINE tumors , *RESEARCH methodology , *UTERINE fibroids , *ESTROGEN , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *MENORRHAGIA , *BLIND experiment , *RESEARCH funding , *HOT flashes , *DISEASE complications - Abstract
Background: Uterine fibroids are a common cause of heavy menstrual bleeding and pain. Treatment with the combination of relugolix (an oral gonadotropin-releasing hormone-receptor antagonist), estradiol, and norethindrone acetate, administered once daily, may have efficacy in women with uterine fibroids and heavy bleeding while avoiding hypoestrogenic effects.Methods: We conducted two replicate international, double-blind, 24-week, phase 3 trials involving women with fibroid-associated heavy menstrual bleeding. Participants were randomly assigned in a 1:1:1 ratio to receive once-daily placebo, relugolix combination therapy (40 mg of relugolix, 1 mg of estradiol, and 0.5 mg of norethindrone acetate), or delayed relugolix combination therapy (40 mg of relugolix monotherapy, followed by relugolix combination therapy, each for 12 weeks). The primary efficacy end point in each trial was the percentage of participants with a response (volume of menstrual blood loss <80 ml and a ≥50% reduction in volume from baseline) in the relugolix combination therapy group, as compared with the placebo group. Key secondary end points were amenorrhea, volume of menstrual blood loss, distress from bleeding and pelvic discomfort, anemia, pain, fibroid volume, and uterine volume. Safety and bone mineral density were assessed.Results: A total of 388 women in trial L1 and 382 in trial L2 underwent randomization. A total of 73% of the participants in the relugolix combination therapy group in trial L1 and 71% of those in trial L2 had a response (primary end point), as compared with 19% and 15%, respectively, of those in the placebo groups (P<0.001 for both comparisons). Both relugolix combination therapy groups had significant improvements, as compared with the placebo groups, in six of seven key secondary end points, including measures of menstrual blood loss (including amenorrhea), pain, distress from bleeding and pelvic discomfort, anemia, and uterine volume, but not fibroid volume. The incidence of adverse events was similar with relugolix combination therapy and placebo. Bone mineral density was similar with relugolix combination therapy and placebo but decreased with relugolix monotherapy.Conclusions: Once-daily relugolix combination therapy resulted in a significant reduction in menstrual bleeding, as compared with placebo, and preserved bone mineral density in women with uterine fibroids. (Funded by Myovant Sciences; LIBERTY 1 [L1] and LIBERTY 2 [L2] ClinicalTrials.gov numbers, NCT03049735 and NCT03103087, respectively.). [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
25. PREGNANCY AND COVID-19.
- Author
-
Wastnedge, Elizabeth A. N., Reynolds, Rebecca M., van Boeckel, Sara R., Stock, Sarah J., Denison, Fiona C., Maybin, Jacqueline A., and Critchley, Hilary O. D.
- Abstract
There are many unknowns for pregnant women during the coronavirus disease 2019 (COVID-19) pandemic. Clinical experience of pregnancies complicated with infection by other coronaviruses e.g., Severe Acute Respiratory Syndrome (SARS) and Middle Eastern Respiratory Syndrome, has led to pregnant woman being considered potentially vulnerable to severe SARS-CoV-2 infection. Physiological changes during pregnancy have a significant impact on the immune system, respiratory system, cardiovascular function, and coagulation. These may have positive or negative effects on COVID-19 disease progression. The impact of SARS-CoV-2 in pregnancy remains to be determined, and a concerted, global effort is required to determine the effects on implantation, fetal growth and development, labor, and neonatal health. Asymptomatic infection presents a further challenge regarding service provision, prevention, and management. Besides the direct impacts of the disease, a plethora of indirect consequences of the pandemic adversely affect maternal health, including reduced access to reproductive health services, increased mental health strain, and increased socioeconomic deprivation. In this review, we explore the current knowledge of COVID-19 in pregnancy and highlight areas for further research to minimize its impact for women and their children. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. The need for serum biomarker development for diagnosing and excluding tubal ectopic pregnancy.
- Author
-
HORNE, ANDREW W., DUNCAN, W. COLIN, CRITCHLEY, HILARY O. D., and Critchley, Hilary Od
- Subjects
- *
BIOMARKERS , *TUBAL pregnancy , *DIAGNOSIS , *ESTRADIOL , *BLOOD proteins , *MISCARRIAGE - Abstract
The author comments on the importance of developing new biomarkers for use in diagnosing and excluding tubal ectopic pregnancy. Problems in diagnosing tubal ectopic pregnancy lead to delays in providing early treatment, which is vital in reducing morbidity and mortality. Certain biomarkers, such as estradiol and pregnancy associated plasma protein A, have been shown to be ineffective in distinguishing a tubal ectopic pregnancy from a non-viable intrauterine pregnancy or miscarriage.
- Published
- 2010
- Full Text
- View/download PDF
27. Profiling the expression and function of oestrogen receptor isoform ER46 in human endometrial tissues and uterine natural killer cells.
- Author
-
Gibson, Douglas A, Esnal-Zufiaurre, Arantza, Bajo-Santos, Cristina, Collins, Frances, Critchley, Hilary O D, and Saunders, Philippa T K
- Subjects
- *
KILLER cells , *MEMBRANE proteins , *VASCULAR remodeling , *CELL motility , *CELL membranes , *ESTROGEN , *ESTROGEN antagonists , *PROTEINS , *RESEARCH , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *UTERUS , *COMPARATIVE studies , *RESEARCH funding , *ENDOMETRIUM - Abstract
Study Question: Does the oestrogen receptor isoform, ER46, contribute to regulation of endometrial function?Summary Answer: ER46 is expressed in endometrial tissues, is the predominant ER isoform in first trimester decidua and is localised to the cell membrane of uterine natural killer (uNK) cells where activation of ER46 increases cell motility.What Is Known Already: Oestrogens acting via their cognate receptors are essential regulators of endometrial function and play key roles in establishment of pregnancy. ER46 is a 46-kDa truncated isoform of full length ERα (ER66, encoded by ESR1) that contains both ligand- and DNA-binding domains. Expression of ER46 in the human endometrium has not been investigated previously. ER46 is located at the cell membrane of peripheral blood leukocytes and mediates rapid responses to oestrogens. uNK cells are a phenotypically distinct (CD56brightCD16-) population of tissue-resident immune cells that regulate vascular remodelling within the endometrium and decidua. We have shown that oestrogens stimulate rapid increases in uNK cell motility. Previous characterisation of uNK cells suggests they are ER66-negative, but expression of ER46 has not been characterised. We hypothesise that uNK cells express ER46 and that rapid responses to oestrogens are mediated via this receptor.Study Design, Size, Duration: This laboratory-based study used primary human endometrial (n = 24) and decidual tissue biopsies (n = 30) as well as uNK cells which were freshly isolated from first trimester human decidua (n = 18).Participants/materials, Setting, Methods: Primary human endometrial and first trimester decidual tissue biopsies were collected using methods approved by the local institutional ethics committee (LREC/05/51104/12 and LREC/10/51402/59). The expression of ERs (ER66, ER46 and ERβ) was assessed by quantitative PCR, western blot and immunohistochemistry. uNK cells were isolated from first-trimester human decidua by magnetic bead sorting. Cell motility of uNK cells was measured by live cell imaging: cells were treated with 17β-oestradiol conjugated to bovine serum albumin (E2-BSA, 10 nM equivalent), the ERβ-selective agonist 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN; 10 nM) or dimethylsulphoxide vehicle control.Main Results and the Role Of Chance: ER46 was detected in proliferative and secretory phase tissues by western blot and was the predominant ER isoform in first-trimester decidua samples. Immunohistochemistry revealed that ER46 was co-localised with ER66 in cell nuclei during the proliferative phase but detected in both the cytoplasm and cell membrane of stromal cells in the secretory phase and in decidua. Triple immunofluorescence staining of decidua tissues identified expression of ER46 in the cell membrane of CD56-positive uNK cells which were otherwise ER66-negative. Profiling of isolated uNK cells confirmed expression of ER46 by quantitative PCR and western blot and localised ER46 protein to the cell membrane by immunocytochemistry. Functional analysis of isolated uNK cells using live cell imaging demonstrated that activation of ER46 with E2-BSA significantly increased uNK cell motility.Large Scale Data: N/A.Limitations, Reasons For Caution: Expression pattern in endometrial tissue was only determined using samples from proliferative and secretory phases. Assessment of first trimester decidua samples was from a range of gestational ages, which may have precluded insights into gestation-specific changes in these tissues. Our results are based on in vitro responses of primary human cells and we cannot be certain that similar mechanisms occur in situ.Wider Implications Of the Findings: E2 is an essential regulator of reproductive competence. This study provides the first evidence for expression of ER46 in the human endometrium and decidua of early pregnancy. We describe a mechanism for regulating the function of human uNK cells via expression of ER46 and demonstrate that selective targeting with E2-BSA regulates uNK cell motility. These novel findings identify a role for ER46 in the human endometrium and provide unique insight into the importance of membrane-initiated signalling in modulating the impact of E2 on uNK cell function in women. Given the importance of uNK cells to regulating vascular remodelling in early pregnancy and the potential for selective targeting of ER46, this may be an attractive future therapeutic target in the treatment of reproductive disorders.Study Funding/competing Interest(s): These studies were supported by Medical Research Council (MRC) Programme Grants G1100356/1 and MR/N024524/1 to PTKS. H.O.D.C. was supported by MRC grant G1002033. The authors declare no competing interests related to the published work. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
28. A role for steroid sulphatase in intracrine regulation of endometrial decidualisation.
- Author
-
Gibson, Douglas A., Foster, Paul A., Simitsidellis, Ioannis, Critchley, Hilary O. D., Kelepouri, Olympia, Collins, Frances, and Saunders, Philippa T. K.
- Subjects
- *
SULFATASES , *STEROID hormones , *ENDOMETRIAL diseases , *PREGNANCY complications , *BIOACTIVE compounds , *GENE expression - Abstract
In women, establishment of pregnancy is dependent upon 'fine-tuning' of the endometrial microenvironment, which is mediated by terminal differentiation (decidualisation) of endometrial stromal fibroblasts (ESFs). We have demonstrated that intracrine steroid metabolism plays a key role in regulating decidualisation and is essential for time-dependent expression of key factors required for endometrial receptivity. The primary aim of the current study was to determine whether sulphated steroids can act as precursors to bioactive sex steroids during decidualisation. We used primary human ESF and a robust in vitro model of decidualisation to assess the expression of genes associated with sulphation, desulphation and transport of sulphated steroids in human ESF as well as the impact of the steroid sulphatase (STS) inhibitor STX64 (Irosustat). We found evidence for an increase in both expression and activity of STS in response to a decidualisation stimulus with abrogation of oestrone biosynthesis and decreased secretion of the decidualisation marker IGFBP1 in the presence of STX64. These results provide novel insight into the contribution of STS to the intracrine regulation of decidualisation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
29. Development of a Bayesian response-adaptive trial design for the Dexamethasone for Excessive Menstruation study.
- Author
-
Hansen, Christian Holm, Warner, Pamela, Parker, Richard A., Walker, Brian R., Critchley, Hilary O. D., Weir, Christopher J., Holm Hansen, Christian, and Critchley, Hilary Od
- Subjects
- *
MENSTRUATION disorders , *DEXAMETHASONE , *BAYESIAN analysis , *LINEAR statistical models , *STATISTICAL software , *PLACEBOS , *THERAPEUTICS - Abstract
It is often unclear what specific adaptive trial design features lead to an efficient design which is also feasible to implement. This article describes the preparatory simulation study for a Bayesian response-adaptive dose-finding trial design. Dexamethasone for Excessive Menstruation aims to assess the efficacy of Dexamethasone in reducing excessive menstrual bleeding and to determine the best dose for further study. To maximise learning about the dose response, patients receive placebo or an active dose with randomisation probabilities adapting based on evidence from patients already recruited. The dose-response relationship is estimated using a flexible Bayesian Normal Dynamic Linear Model. Several competing design options were considered including: number of doses, proportion assigned to placebo, adaptation criterion, and number and timing of adaptations. We performed a fractional factorial study using SAS software to simulate virtual trial data for candidate adaptive designs under a variety of scenarios and to invoke WinBUGS for Bayesian model estimation. We analysed the simulated trial results using Normal linear models to estimate the effects of each design feature on empirical type I error and statistical power. Our readily-implemented approach using widely available statistical software identified a final design which performed robustly across a range of potential trial scenarios. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
30. Targeting lysyl oxidase reduces peritoneal fibrosis.
- Author
-
Harlow, Christopher R., Wu, Xuan, van Deemter, Marielle, Gardiner, Fiona, Poland, Craig, Green, Rebecca, Sarvi, Sana, Brown, Pamela, Kadler, Karl E., Lu, Yinhui, Mason, J. Ian, Critchley, Hilary O. D., and Hillier, Stephen G.
- Subjects
- *
PERITONEUM diseases , *LYSYL oxidase , *FIBROSIS , *ABDOMINAL surgery , *PELVIC pain - Abstract
Background: Abdominal surgery and disease cause persistent abdominal adhesions, pelvic pain, infertility and occasionally, bowel obstruction. Current treatments are ineffective and the aetiology is unclear, although excessive collagen deposition is a consistent feature. Lysyl oxidase (Lox) is a key enzyme required for crosslinking and deposition of insoluble collagen, so we investigated whether targeting Lox might be an approach to reduce abdominal adhesions. Methods: Female C57Bl/6 mice were treated intraperitoneally with multiwalled carbon nanotubes (NT) to induce fibrosis, together with chemical (ß-aminoproprionitrile–BAPN) or miRNA Lox inhibitors, progesterone or dexamethasone. Fibrotic lesions on the diaphragm, and expression of fibrosis-related genes in abdominal wall peritoneal mesothelial cells (PMC) were measured. Effects of BAPN and dexamethasone on collagen fibre alignment were observed by TEM. Isolated PMC were cultured with interleukin-1 alpha (IL-1α) and progesterone to determine effects on Lox mRNA in vitro. Results: NT-induced fibrosis and collagen deposition on the diaphragm was ameliorated by BAPN, Lox miRNA, or steroids. BAPN and dexamethasone disrupted collagen fibres. NT increased PMC Lox, Col1a1, Col3a1 and Bmp1 mRNA, which was inhibited by steroids. Progesterone significantly inhibited IL-1α induced Lox expression by PMC in vitro. Conclusion: Our results provide proof-of-concept that targeting peritoneal Lox could be an effective approach in ameliorating fibrosis and adhesion development. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
31. Gabapentin for the Management of Chronic Pelvic Pain in Women (GaPP1): A Pilot Randomised Controlled Trial.
- Author
-
Lewis, Steff C., Bhattacharya, Siladitya, Wu, Olivia, Vincent, Katy, Jack, Stuart A., Critchley, Hilary O. D., Porter, Maureen A., Cranley, Denise, Wilson, John A., and Horne, Andrew W.
- Subjects
- *
PELVIC pain treatment , *PELVIC pain , *GABAPENTIN , *WOMEN'S health , *DRUG efficacy , *RANDOMIZED controlled trials , *PATIENTS , *THERAPEUTICS - Abstract
Chronic pelvic pain (CPP) affects 2.1–24% of women. Frequently, no underlying pathology is identified, and the pain is difficult to manage. Gabapentin is prescribed for CPP despite no robust evidence of efficacy. We performed a pilot trial in two UK centres to inform the planning of a future multicentre RCT to evaluate gabapentin in CPP management. Our primary objective was to determine levels of participant recruitment and retention. Secondary objectives included estimating potential effectiveness, acceptability to participants of trial methodology, and cost-effectiveness of gabapentin. Women with CPP and no obvious pelvic pathology were assigned to an increasing regimen of gabapentin (300-2700mg daily) or placebo. We calculated the proportion of eligible women randomised, and of randomised participants who were followed up to six months. The analyses by treatment group were by intention-to-treat. Interviews were conducted to evaluate women’s experiences of the trial. A probabilistic decision analytical model was used to estimate cost-effectiveness. Between September 2012–2013, 47 women (34% of those eligible) were randomised (22 to gabapentin, 25 to placebo), and 25 (53%) completed six-month follow-up. Participants on gabapentin had less pain (BPI difference 1.72 points, 95% CI:0.07–3.36), and an improvement in mood (HADS difference 4.35 points, 95% CI:1.97–6.73) at six months than those allocated placebo. The majority of participants described their trial experience favorably. At the UK threshold for willingness-to-pay, the probabilities of gabapentin or no treatment being cost-effective are similar. A pilot trial assessing gabapentin for CPP was feasible, but uncertainty remains, highlighting the need for a large definitive trial. Trial registration: Controlled-Trials.com [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
32. Unbiased and Efficient Estimation of the Volume of the Fibroid Uterus Using the Cavalieri Method and Magnetic Resonance Imaging.
- Author
-
Thrippleton, Michael J., Munro, Kirsty I., McKillop, Graham, Newby, David E., Marshall, Ian, Roberts, Neil, and Critchley, Hilary O. D.
- Subjects
- *
VOLUME measurements , *MAGNETIC resonance imaging , *UTERINE fibroids , *CALIPERS , *SMOOTH muscle tumors - Abstract
The aim of our study was to develop a reliable technique for measuring volume of the fibroid uterus using Magnetic Resonance Imaging. We applied the Cavalieri method and standard calliper technique to measure the volume of the uterus and largest fibroid in 26 patients, and results were compared with “gold-standard” planimetry measurements. We found Cavalieri measurements to be unbiased, while calliper measurements systematically underestimated uterine volume (− 13.2%, P < 10−5) and had greater variance. Repeatability was similar for the 2 techniques (standard deviation [SD] = 4.0%-6.9%). Reproducibility of Cavalieri measurements was higher for measurement of uterine (SD = 9.0%) than fibroid volume (SD = 19.1%), whereas the reproducibility of calliper measurements was higher for fibroid (SD = 9.1%) than uterine volume (SD = 15.9%). The additional measurement time for the Cavalieri method was approximately 1 to 2 minutes. In conclusion, the Cavalieri method permits more accurate measurement of uterine and fibroid volumes and is suitable for application in both clinical practice and scientific research. [ABSTRACT FROM PUBLISHER]
- Published
- 2015
- Full Text
- View/download PDF
33. Abnormal uterine bleeding: advantages of formal classification to patients, clinicians and researchers.
- Author
-
Madhra, Mayank, Fraser, Ian S., Munro, Malcolm G., and Critchley, Hilary O. D.
- Subjects
- *
UTERINE hemorrhage , *HEMORRHAGE , *MENSTRUATION disorders , *WOMEN'S health , *FEMALE reproductive organ diseases - Abstract
Objective To highlight the advantages of formal classification of causes of abnormal uterine bleeding from a clinical and scientific perspective. Design Review and recommendations for local implementation. Setting In the past, research in the field of menstrual disorders has not been funded adequately with respect to the impact of symptoms on individuals, healthcare systems and society. This was confounded by a diverse terminology, which lead to confusion between clinical and scientific groups, ultimately harming the underlying evidence base. To address this, a formal classification system ( PALM- COEIN) for the causes of abnormal uterine bleeding has been published for worldwide use by FIGO (International Federation of Gynecology and Obstetrics). Population and main outcome measures This commentary explains problems created by the prior absence of such a system, the potential advantages stemming from its use, and practical suggestions for local implementation. Results and conclusions The PALM- COEIN classification is applicable globally and, as momentum gathers, will ameliorate recurrence of historic problems, and harmonise reporting of clinical and scientific research to facilitate future progress in women's health. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
34. Quantitative Serial MRI of the Treated Fibroid Uterus.
- Author
-
Munro, Kirsty I., Thrippleton, Michael J., Williams, Alistair R. W., McKillop, Graham, Walker, Jane, Horne, Andrew W., Newby, David E., Anderson, Richard A., Semple, Scott I., Marshall, Ian, Lewis, Steff C., Millar, Robert P., Bastin, Mark E., and Critchley, Hilary O. D.
- Subjects
- *
MAGNETIC resonance imaging , *BIOMARKERS , *NONINVASIVE diagnostic tests , *DRUG administration , *CLINICAL trials , *RADIOLOGY ,UTERINE fibroid treatment - Abstract
Objective: There are no long-term medical treatments for uterine fibroids, and non-invasive biomarkers are needed to evaluate novel therapeutic interventions. The aim of this study was to determine whether serial dynamic contrast-enhanced MRI (DCE-MRI) and magnetization transfer MRI (MT-MRI) are able to detect changes that accompany volume reduction in patients administered GnRH analogue drugs, a treatment which is known to reduce fibroid volume and perfusion. Our secondary aim was to determine whether rapid suppression of ovarian activity by combining GnRH agonist and antagonist therapies results in faster volume reduction. Methods: Forty women were assessed for eligibility at gynaecology clinics in the region, of whom thirty premenopausal women scheduled for hysterectomy due to symptomatic fibroids were randomized to three groups, receiving (1) GnRH agonist (Goserelin), (2) GnRH agonist+GnRH antagonist (Goserelin and Cetrorelix) or (3) no treatment. Patients were monitored by serial structural, DCE-MRI and MT-MRI, as well as by ultrasound and serum oestradiol concentration measurements from enrolment to hysterectomy (approximately 3 months). Results: A volumetric treatment effect assessed by structural MRI occurred by day 14 of treatment (9% median reduction versus 9% increase in untreated women; P = 0.022) and persisted throughout. Reduced fibroid perfusion and permeability assessed by DCE-MRI occurred later and was demonstrable by 2–3 months (43% median reduction versus 20% increase respectively; P = 0.0093). There was no apparent treatment effect by MT-MRI. Effective suppression of oestradiol was associated with early volume reduction at days 14 (P = 0.041) and 28 (P = 0.0061). Conclusion: DCE-MRI is sensitive to the vascular changes thought to accompany successful GnRH analogue treatment of uterine fibroids and should be considered for use in future mechanism/efficacy studies of proposed fibroid drug therapies. GnRH antagonist administration does not appear to accelerate volume reduction, though our data do support the role of oestradiol suppression in GnRH analogue treatment of fibroids. Trial Registration: ClinicalTrials.gov NCT00746031 [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
35. Evidence from a Mouse Model That Epithelial Cell Migration and Mesenchymal-Epithelial Transition Contribute to Rapid Restoration of Uterine Tissue Integrity during Menstruation.
- Author
-
Cousins, Fiona L., Murray, Alison, Esnal, Arantza, Gibson, Douglas A., Critchley, Hilary O. D., and Saunders, Philippa T. K.
- Subjects
- *
EPITHELIAL cells , *CELL migration , *MESENCHYMAL stem cells , *ENDOMETRIUM , *MENSTRUATION , *INFLAMMATION , *LABORATORY mice , *ANATOMY - Abstract
Background: In women dynamic changes in uterine tissue architecture occur during each menstrual cycle. Menses, characterised by the shedding of the upper functional layer of the endometrium, is the culmination of a cascade of irreversible changes in tissue function including stromal decidualisation, inflammation and production of degradative enzymes. The molecular mechanisms that contribute to the rapid restoration of tissue homeostasis at time of menses are poorly understood. Methodology: A modified mouse model of menses was developed to focus on the events occurring within the uterine lining during endometrial shedding/repair. Decidualisation, vaginal bleeding, tissue architecture and cell proliferation were evaluated at 4, 8, 12, and 24 hours after progesterone (P4) withdrawal; mice received a single injection of bromodeoxyuridine (BrdU) 90 mins before culling. Expression of genes implicated in the regulation of mesenchymal to epithelial transition (MET) was determined using a RT2 PCR profiler array, qRTPCR and bioinformatic analysis. Principal Findings: Mice exhibited vaginal bleeding between 4 and 12 hours after P4 withdrawal, concomitant with detachment of the decidualised cell mass from the basal portion of the endometrial lining. Immunostaining for BrdU and pan cytokeratin revealed evidence of epithelial cell proliferation and migration. Cells that appeared to be in transition from a mesenchymal to an epithelial cell identity were identified within the stromal compartment. Analysis of mRNAs encoding genes expressed exclusively in the epithelial or stromal compartments, or implicated in MET, revealed dynamic changes in expression, consistent with a role for reprogramming of mesenchymal cells so that they could contribute to re-epithelialisation. Conclusions/Significance: These studies have provided novel insights into the cellular processes that contribute to re-epithelialisation post-menses implicating both epithelial cell migration and mesenchymal cell differentiation in restoration of an intact epithelial cell layer. These insights may inform development of new therapies to induce rapid healing in the endometrium and other tissues and offer hope to women who suffer from heavy menstrual bleeding. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
36. Characterization of the Temporal and Spatial Expression of a Disintegrin and Metalloprotease 17 in the Human Endometrium and Fallopian Tube.
- Author
-
Jowicz, Adam P., Brown, Jeremy K., McDonald, Sarah E., Shaw, Julie L. V., Critchley, Hilary O. D., and Horne, Andrew W.
- Subjects
- *
DISINTEGRINS , *METALLOPROTEINASES , *FALLOPIAN tubes , *MUCINS , *OLIGOSACCHARIDES , *ENDOMETRIUM , *QUANTITATIVE research - Abstract
Metalloproteinases are thought to mediate shedding of mucins from the endometrium surface, exposing oligosaccharide ligands involved in implantation. We hypothesized that a disintegrin and metalloprotease 17 (ADAM17) is upregulated during the “window of implantation” in human endometrium but not in fallopian tube (FT) where implantation is pathological. Endometrial and FT expression of ADAM17 throughout the menstrual cycle was determined using quantitative reverse-transcription polymerase chain reaction and immunohistochemistry. The ADAM17 transcription was significantly downregulated (P < .01) during the early–midsecretory phase in the endometrium but not in the FT. The ADAM17 was localized to the surface of epithelial cells and was also detected in the endometrial stroma during the late luteal and proliferative phase of the cycle. Physiological levels of estradiol significantly (P < .05) upregulated ADAM17 transcription in vitro. Our observations do not support the role of ADAM17 in shedding of mucins during the window of implantation. The precise role of ADAM17 in the female reproductive tract requires further investigation. [ABSTRACT FROM PUBLISHER]
- Published
- 2013
- Full Text
- View/download PDF
37. Combination Gefitinib and Methotrexate Compared With Methotrexate Alone to Treat Ectopic Pregnancy.
- Author
-
Skubisz, Monika M., Horne, Andrew W., Johns, Terrance G., Nilsson, Ulrika W., Duncan, W. Colin, Wallace, Euan M., Critchley, Hilary O. D., and Tong, Stephen
- Subjects
- *
GEFITINIB , *METHOTREXATE , *ANTINEOPLASTIC agents , *ECTOPIC pregnancy , *PREGNANCY complications , *THERAPEUTICS - Abstract
OBJECTIVE: To determine the safety, tolerability, and efficacy of combination gefitinib and methotrexate to treat ectopic pregnancy. METHODS: We performed a phase I, single-arm (nonrandomized), open-label study. Twelve women with ectopic pregnancies were administered methotrexate (50 mg/m², intramuscular) and 250 mg oral gefitinib in a dose-escalation protocol: one dose (day 1) n=3; three doses (days 1-3) n=3; seven doses (days 1-7) n=6. Efficacy was examined by comparing human chorionic gonadotrophin (hCG) decline and time to resolution with historic controls administered methotrexate only. RESULTS: Common side effects were transient acneiform rash in 67% (8/12) and diarrhea in 42% (5/12) of participants. There was no clinical or biochemical evidence of serious pulmonary, renal, hepatic, or hematologic toxicity. Of six participants with a pretreatment serum hCG level between 1,000 and 3,000 international units/L, hCG levels declined significantly faster than in the control group. Median serum hCG levels by day 7 after treatment were less than one fifth of levels observed among 71 historic controls treated with methotrexate alone (median [interquartile range] hCG in participants 261 [55-1,445] international units/L compared with controls 1,426 [940-2,573]; P=.008). Median time for the ectopic pregnancies to resolve with combination therapy was 34% shorter compared with methotrexate alone (21 days compared with 32 days; P=.018). CONCLUSION: Combination gefitinib and methotrexate has potential as a treatment for ectopic pregnancy but is commonly associated with minor side effects such as transient rash and diarrhea. The treatment requires validation of safety and efficacy in a larger trial. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
38. Uterine NK Cells Regulate Endometrial Bleeding in Women and Are Suppressed by the Progesterone Receptor Modulator Asoprisnil.
- Author
-
Wilkens, Julia, Male, Victoria, Ghazal, Peter, Forster, Thorsten, Gibson, Douglas A., Williams, Alistair R. W., Brito-Mutunayagam, Savita L., Craigon, Marie, Lourenco, Paula, Cameron, Iain T., Chwalisz, Kristof, Moffett, Ashley, and Critchley, Hilary O. D.
- Subjects
- *
KILLER cells , *UTERINE hemorrhage , *PROGESTERONE receptors , *INTERLEUKIN-15 , *ENDOMETRIAL diseases , *IMMUNOSTAINING , *PREVENTION , *PHYSIOLOGY - Abstract
Uterine NK cells (uNK) play a role in the regulation of placentation, but their functions in nonpregnant endometrium are not understood. We have previously reported suppression of endometrial bleeding and alteration of spiral artery morphology in women exposed to asoprisnil, a progesterone receptor modulator. We now compare global endometrial gene expression in asoprisnil-treated versus control women, and we demonstrate a statistically significant reduction of genes in the IL-15 pathway, known to play a key role in uNK development and function. Suppression of IL-15 by asoprisnil was also observed at mRNA level (p < 0.05), and immunostaining for NK cell marker CD56 revealed a striking reduction of uNK in asoprisnil-treated endometrium (p < 0.001). IL-15 levels in normal endometrium are progesterone-responsive. Progesterone receptor (PR) positive stromal cells transcribe both IL-15 and IL-15RA. Thus, the response of stromal cells to progesterone will be to increase IL-15 trans-presentation to uNK, supporting their expansion and differentiation. In asoprisnil-treated endometrium, there is a marked downregulation of stromal PR expression and virtual absence of uNK. These novel findings indicate that the IL-15 pathway provides a missing link in the complex interplay among endometrial stromal cells, uNK, and spiral arteries affecting physiologic and pathologic endometrial bleeding. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
39. Shotgun Proteomics Identifies Serum Fibronectin as a Candidate Diagnostic Biomarker for Inclusion in Future Multiplex Tests for Ectopic Pregnancy.
- Author
-
Brown, Jeremy K., Lauer, Katarina B., Ironmonger, Emily L., Inglis, Neil F., Bourne, Tom H., Critchley, Hilary O. D., and Horne, Andrew W.
- Subjects
- *
ECTOPIC pregnancy , *PROTEOMICS , *FIBRONECTINS , *SERUM , *BIOMARKERS , *RECEIVER operating characteristic curves , *MEDICAL emergencies , *DIAGNOSIS - Abstract
Ectopic pregnancy (EP) is difficult to diagnose early and accurately. Women often present at emergency departments in early pregnancy with a ‘pregnancy of unknown location’ (PUL), and diagnosis and exclusion of EP is challenging due to a lack of reliable biomarkers. The objective of this study was to identify novel diagnostic biomarkers for EP. Shotgun proteomics, incorporating combinatorial-ligand library pre-fractionation, was used to interrogate pooled sera (n = 40) from women undergoing surgery for EP, termination of viable intrauterine pregnancy and management of non-viable intrauterine pregnancy. Western blot was used to validate results in individual sera. ELISAs were developed to interrogate sera from women with PUL (n = 120). Sera were collected at time of first symptomatic presentation and categorized according to pregnancy outcome. The main outcome measures were differences between groups and area under the receiver operating curve (ROC). Proteomics identified six biomarker candidates. Western blot detected significant differences in levels of two of these candidates. ELISA of sera from second cohort revealed that these differences were only significant for one of these candidates, fibronectin. ROC analysis of ability of fibronectin to discriminate EP from other pregnancy outcomes suggested that fibronectin has diagnostic potential (ROC 0.6439; 95% CI 0.5090 to 0.7788; P>0.05), becoming significant when ‘ambiguous’ medically managed PUL excluded from analysis (ROC 0.6538; 95% CI 0.5158 to 0.7918; P<0.05). Fibronectin may make a useful adjunct to future multiplex EP diagnostic tests. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
40. Has increased clinical experience with methotrexate reduced the direct costs of medical management of ectopic pregnancy compared to surgery?
- Author
-
Westaby, Daniel T., Wu, Olivia, Duncan, W. Colin, Critchley, Hilary O. D., Tong, Stephen, and Horne, Andrew W.
- Subjects
- *
ECTOPIC pregnancy , *MEDICAL care costs , *ANTINEOPLASTIC agents , *CONFIDENCE intervals , *PREGNANCY complications - Abstract
Background: There is a debate about the cost-efficiency of methotrexate for the management of ectopic pregnancy (EP), especially for patients presenting with serum human chorionic gonadotrophin levels of >1500 IU/L. We hypothesised that further experience with methotrexate, and increased use of guideline-based protocols, has reduced the direct costs of management with methotrexate. Methods: We conducted a retrospective cost analysis on women treated for EP in a large UK teaching hospital to (1) investigate whether the cost of medical management is less expensive than surgical management for those patients eligible for both treatments and (2) to compare the cost of medical management for women with hCG concentrations 1500-3000 IU/L against those with similar hCG concentrations that elected for surgery. Three distinct treatment groups were identified: (1) those who had initial medical management with methotrexate, (2) those who were eligible for initial medical management but chose surgery ('elected' surgery) and (3) those who initially 'required' surgery and did not meet the eligibility criteria for methotrexate. We calculated the costs from the point of view of the National Health Service (NHS) in the UK. We summarised the cost per study group using the mean, standard deviation, median and range and, to account for the skewed nature of the data, we calculated 95% confidence intervals for differential costs using the nonparametric bootstrap method. Results: Methotrexate was £1179 (CI 819-1550) per patient cheaper than surgery but there were no significant savings with methotrexate in women with hCG >1500 IU/L due to treatment failures. Conclusions: Our data support an ongoing unmet economic need for better medical treatments for EP with hCG >1500 IU/L. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
41. Sex Steroid Hormones and Reproductive Disorders: Impact on Women’s Health.
- Author
-
Fauser, Bart C. J. M., Laven, Joop S. E., Tarlatzis, Basil C., Moley, Kelle H., Critchley, Hilary O. D., Taylor, Robert N., Berga, Sarah L., Mermelstein, Paul G., Devroey, Paul, Gianaroli, Luca, D’Hooghe, Thomas, Vercellini, Paolo, Hummelshoj, Lone, Rubin, Susan, Goverde, Angelique J., Leo, Vincenzo De, and Petraglia, Felice
- Subjects
- *
STEROID hormones , *WOMEN'S health , *REPRODUCTION , *ENDOMETRIOSIS , *ESTROGEN receptors , *PROGESTERONE receptors , *ANDROGENS - Abstract
The role of sex steroid hormones in reproductive function in women is well established. However, in the last two decades it has been shown that receptors for estrogens, progesterone and androgens are expressed in non reproductive tissue /organs (bone, brain, cardiovascular system) playing a role in their function. Therefore, it is critical to evaluate the impact of sex steroid hormones in the pathophysiology of some diseases (osteoporosis, Alzheimer, atherosclerosis). In particular, women with primary ovarian insufficiency, polycystic ovary syndrome, endometriosis and climacteric syndrome may have more health problems and therefore an hormonal treatment may be crucial for these women. [ABSTRACT FROM PUBLISHER]
- Published
- 2011
- Full Text
- View/download PDF
42. Ectopic Pregnancy as a Model to Identify Endometrial Genes and Signaling Pathways Important in Decidualization and Regulated by Local Trophoblast.
- Author
-
Duncan, W. Colin, Shaw, Julie L. V., Burgess, Stewart, McDonald, Sarah E., Critchley, Hilary O. D., and Horne, Andrew W.
- Subjects
- *
ENDOMETRIUM , *TROPHOBLAST , *ECTOPIC pregnancy , *FETAL development , *HISTOLOGY , *POLYMERASE chain reaction , *ANTIGEN presentation , *WNT genes , *KILLER cells - Abstract
The endometrium in early pregnancy undergoes decidualization and functional changes induced by local trophoblast, which are not fully understood. We hypothesized that endometrium from tubal ectopic pregnancy (EP) could be interrogated to identify novel genes and pathways involved in these processes. Gestation-matched endometrium was collected from women with EP (n = 11) and intrauterine pregnancies (IUP) (n = 13). RNA was extracted from the tissue. In addition, tissues were prepared for histological analysis for degree of decidualization. We compared a) the samples from EP that were decidualized (n = 6) with non-decidualized samples (n = 5), and b) the decidualized EP (n = 6) with decidualizationmatched IUP (n = 6) samples using an Affymetrix gene array platform, with Ingenuity Pathway Analysis, combined with quantitative RT-PCR. Expression of PRL and IGFBP1 was used to confirm the degree of decidualization in each group. There were no differences in PRL or IGFBP1 expression in the decidualization-matched samples but a marked reduction (P<0.001) in the non-decidualized samples. Decidualization was associated with increased expression of 428 genes including SCARA5 (181-fold), DKK1 (71-fold) and PROK1 (32-fold), and decreased expression of 230 genes including MMP-7 (35-fold) and SFRP4 (21-fold). The top canonical pathways associated with these differentially expressed genes were Natural Killer Cell and Wnt/ b-Catenin signaling. Local trophoblast was associated with much less alteration of endometrial gene expression with an increase in 56 genes, including CSH1 (8-fold), and a reduction in 29 genes including CRISP3 (8-fold). The top associated canonical pathway was Antigen Presentation. The study of endometrium from tubal EP may promote novel insights into genes involved in decidualization and those influenced by factors from neighboring trophoblast. This has afforded unique information not highlighted by previous studies and adds to our understanding of the endometrium in early pregnancy. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
43. Reconstruction of Endometrium from Human Endometrial Side Population Cell Lines.
- Author
-
Cervello, Irene, Mas, Aymara, Gil-Sanchis, Claudia, Peris, Laura, Faus, Amparo, Saunders, Philippa T. K., Critchley, Hilary O. D., and Simón, Carlos
- Subjects
- *
SOMATIC cells , *ENDOMETRIAL surgery , *CELL lines , *LABORATORY mice , *SUBCUTANEOUS surgery , *CRYOPRESERVATION of organs, tissues, etc. , *TELOMERASE , *BIOMARKERS , *PROGESTERONE receptors - Abstract
Endometrial regeneration is mediated, at least in part, by the existence of a specialized somatic stem cell (SSC) population recently identified by several groups using the side population (SP) technique. We previously demonstrated that endometrial SP displays genotypic, phenotypic and the functional capability to develop human endometrium after subcutaneous injection in NOD-SCID mice. We have now established seven human endometrial SP (hESP) cell lines (ICE 1-7): four from the epithelial and three from the stromal fraction, respectively. SP cell lines were generated under hypoxic conditions based on their cloning efficiency ability, cultured for 12-15 passages (20 weeks) and cryopreserved. Cell lines displayed normal 46XX karyotype, intermediate telomerase activity pattern and expressed mRNAs encoding proteins that are considered characteristic of undifferentiated cells (Oct-4, GDF3, DNMT3B, Nanog, GABR3) and those of mesodermal origin (WT1, Cardiac Actin, Enolase, Globin, REN). Phenotype analysis corroborated their epithelial (CD9+) or stromal (vimentin+) cell origin and mesenchymal (CD90+, CD73+ and CD45-) attributes. Markers considered characteristic of ectoderm or endoderm were not detected. Cells did not express either estrogen receptor alpha (ERa) or progesterone receptor (PR). The hESP cell lines were able to differentiate in vitro into adipocytes and osteocytes, which confirmed their mesenchymal origin. Finally, we demonstrated their ability to generate human endometrium when transplanted beneath the renal capsule of NOD-SCID mice. These findings confirm that SP cells exhibit key features of human endometrial SSC and open up new possibilities for the understanding of gynecological disorders such as endometriosis or Asherman syndrome. Our cell lines can be a valuable model to investigate new targets for endometrium proliferation in endometriosis. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
44. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover P. M. Crofton et al. Physiological vs standard sex steroid replacement.
- Author
-
Crofton, Patricia M., Evans, Nancy, Bath, Louise E., Warner, Pamela, Whitehead, Tessa J., Critchley, Hilary O. D., Kelnar, Christopher J. H., and Wallace, W. Hamish B.
- Subjects
- *
STEROIDS , *PREMATURE ovarian failure , *HORMONE therapy , *PROGESTERONE , *YOUNG women , *ALKALINE phosphatase - Abstract
The aim of this exploratory study was to establish whether we could improve skeletal health with a physiological regimen of SSR in young women with premature ovarian failure (POF). In an open-label randomized controlled crossover trial, 34 women with POF were randomized to 4-week cycles of pSSR (transdermal oestradiol, 100 μg daily for week 1, 150 μg for weeks 2-4; vaginal progesterone, 200 mg twice daily for weeks 3-4) or standard hormone replacement treatment (sHRT) (oral ethinyloestradiol 30 μg and 1·5 mg norethisterone daily for weeks 1-3, week 4 'pill-free') for 12 months. Bone mineral density (BMD) was measured by DEXA at study entry and after each 12-month treatment period. Blood samples for hormones and markers of bone formation (bone alkaline phosphatase, BALP and type I collagen N-terminal propeptide, PINP) and bone resorption (CrossLaps) were collected pre-/postwashout and after 3, 6 and 12 months of each treatment. Eighteen women, mean 27 (range 19-39) years, completed the study. Both regimens caused similar suppression of LH and FSH. Mean baseline lumbar spine BMD z-score was −0·89 (95% CI −1·27 to −0·51) and increased by +0·17 (CI +0·07 to +0·27) in response to pSSR ( P = 0·003), compared with +0·07 (CI −0·03 to +0·18) during standard HRT ( P = 0·2). During pSSR, the increment in lumbar spine BMD z-score was related positively to oestradiol ( r = +0·49, P = 0·04) and inversely to FSH ( r = −0·65, P = 0·004). Bone formation markers, BALP and P1NP increased in the pSSR arm ( P < 0·001) but decreased in the sHRT arm ( P < 0·01). Both treatments suppressed the bone resorption marker, CrossLaps ( P < 0·001). We conclude that pSSR over 12 months has a beneficial affect on bone mass acquisition on the lumbar spine in women with POF, mediated by increased bone formation and decreased bone resorption. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
45. TGFβ1 Attenuates Expression of Prolactin and IGFBP-1 in Decidualized Endometrial Stromal Cells by Both SMAD-Dependent and SMAD-Independent Pathways.
- Author
-
Kane, Nicole M., Jones, Marius, Brosens, Jan J., Kelly, Rodney W., Saunders, Philippa T. K., and Critchley, Hilary O. D.
- Subjects
- *
MESENCHYMAL stem cells , *PROTEIN hormones , *PITUITARY hormones , *NEUROHORMONES , *ENDOCRINE gynecology , *PROINSULIN , *MESSENGER RNA - Abstract
Background: Decidualization (differentiation) of the endometrial stromal cells during the secretory phase of the menstrual cycle is essential for successful implantation. Transforming Growth Factor β1 (TGFβ1) canonically propagates its actions via SMAD signalling. A role for TGFβ1 in decidualization remains to be established and published data concerning effects of TGFβ1 on markers of endometrial decidualization are inconsistent. Methodology/Principal Findings: Non-pregnant endometrial stromal cells (ESC) and first trimester decidual stromal cells (DSC) were cultured in the presence or absence of a decidualizing stimulus. Incubation of ESCs with TGFβ1 (10 ng/ml) down-regulated the expression of transcripts encoding the decidual marker proteins prolactin (PRL), insulin-like growth factor binding protein-1 (IGFBP-1) and tissue factor (TF). TGFβ1 also inhibited secretion of PRL and IGFBP-1 proteins by ESCs and surprisingly this response preceded down-regulation of their mRNAs. In contrast, DSCs were more refractory to the actions of TGFβ1, characterized by blunted and delayed down-regulation of PRL, IGFBP-1, and TF transcripts, which was not associated with a significant reduction in secretion of PRL or IGFBP-1 proteins. Addition of an antibody directed against TGFβ1 increased expression of IGFBP-1 mRNA in decidualised cells. Knockdown of SMAD 4 using siRNAs abrogated the effect of TGFβ1 on expression of PRL in ESCs but did not fully restore expression of IGFBP-1 mRNA and protein. Conclusions/Significance: TGFβ1 inhibits the expression and secretion of decidual marker proteins. The impact of TGFβ1 on PRL is SMAD-dependent but the impact on IGFBP1 is via an alternative mechanism. In early pregnancy, resistance of DSC to the impact of TGFβ1 may be important to ensure tissue homeostasis. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
46. Prokineticin 1 mediates fetal-maternal dialogue regulating endometrial leukemia inhibitory factor.
- Author
-
Evans, Jemma, Catalano, Rob D., Brown, Pamela, Sherwin, Rob, Critchley, Hilary O. D., Fazleabas, Asgerally T., and Jabbour, Henry N.
- Subjects
- *
PROTEINS , *LEUKEMIA inhibitory factor , *CHORIONIC gonadotropins , *TROPHOBLAST , *MESSENGER RNA , *ENDOMETRIUM , *PREGNANCY - Abstract
Implantation requires communication between a receptive endometrium and a healthy blastocyst. This maternal-embryonic crosstalk involves local mediators within the uterine microenvironment. We demonstrate that a secreted protein, prokineticin 1 (PROK1), expressed in the receptive endometrium and during pregnancy. PROK1 induces expression of leukemia inhibitory factor (LIF) in endometrial epithelial cells and trimester decidua via a Gq-Ca2+-cSrc-mitogen-activated protein kinase kinase-mediated pathway. We show human embryonic chorionic gonadotropin (hCG) induces sequential mRNA expression of PROK1 and LIF in vivo baboon model, in human endometrial epithelial cells, and in first-trimester decidua. We have used micro RNA constructs targeted to PROK1 to demonstrate hCG-mediated LIF expression in the endometrium dependent on prior induction of PROK1. Dual immunohistochemical analysis colocalized expression of luteinizing hormone/chorionic gonadotropin receptor, PROK1, PROKR1, and LIF to the glandular epithelial cells of the first trimester decidual tissue. PROK1 enhances adhesion of trophoblast cells to fibronectin laminin matrices, which are mediated predominantly LIF induction. These data describe a novel signaling pathway mediating maternal-embryonic crosstalk, which embryonic hCG via endometrial PROK1 may a pivotal role in enhancing receptivity and maintaining early pregnancy. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
47. Expression of secretory leukocyte protease inhibitor and elafin in human fallopian tube and in an in-vitro model of Chlamydia trachomatis infection.
- Author
-
King, Anne E, Wheelhouse, Nick, Cameron, Sharon, McDonald, Sarah E, Lee, Kai-Fai, Entrican, Gary, Critchley, Hilary O D, and Horne, Andrew W
- Subjects
- *
RNA metabolism , *CELL culture , *CHLAMYDIA infections , *CHLAMYDIA trachomatis , *COMPARATIVE studies , *FALLOPIAN tubes , *GENES , *RESEARCH methodology , *MEDICAL cooperation , *POLYMERASE chain reaction , *PROTEINS , *RESEARCH , *EVALUATION research , *REVERSE transcriptase polymerase chain reaction , *IN vitro studies - Abstract
Background: Secretory leukocyte protease inhibitor (SLPI) and elafin are anti-protease and anti-microbial molecules with a role in innate immune defence. They have been demonstrated at multiple mucosal surfaces including those of the female reproductive tract.Methods and Results: This study details their expression in human Fallopian tubes (ampullary region) throughout the menstrual cycle (n = 18) and from women with ectopic pregnancy (n = 6), and examined their regulation by infection with Chlamydia trachomatis in an in-vitro model. Quantitative real-time PCR analysis showed that SLPI and elafin were constitutively expressed in the Fallopian tube during the menstrual cycle but were increased in ectopic pregnancy (P < 0.05 versus early-mid luteal phase, P < 0.01 versus all phases, respectively). SLPI and elafin were immunolocalised to the Fallopian tube epithelium in biopsies from non-pregnant women and those with ectopic pregnancy. An in-vitro culture model of C. trachomatis infection of the OE-E6/E7 oviductal epithelial cell line showed that elafin mRNA expression was upregulated in response to chlamydial infection.Conclusion: These data suggest that SLPI and elafin have a role in the innate immune defence of the Fallopian tube in infection and ectopic pregnancy. Their role is likely to include regulation of protease activity, wound healing and tissue remodelling. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
48. Biomarkers in reproductive medicine: the quest for new answers.
- Author
-
Simon, Carlos, Sakkas, Denny, Gardner, David K., and Critchley, Hilary O. D.
- Subjects
- *
REPRODUCTIVE health , *BIOMARKERS , *INDIVIDUALIZED medicine , *EMBRYO implantation , *DURATION of pregnancy , *MISCARRIAGE - Published
- 2015
- Full Text
- View/download PDF
49. CB1 Expression Is Attenuated in Fallopian Tube and Decidua of Women with Ectopic Pregnancy.
- Author
-
Horne, Andrew W., Phillips III, John A., Kane, Nicole, Lourenco, Paula C., McDonald, Sarah E., Williams, Alistair R. W., Simon, Carlos, Dey, Sudhansu K., and Critchley, Hilary O. D.
- Subjects
- *
FALLOPIAN tubes , *ECTOPIC pregnancy , *DISEASES , *CANNABINOIDS , *HUMAN embryo transfer , *IMMUNOHISTOCHEMISTRY , *ENDOMETRIUM , *GENETIC polymorphisms , *MESSENGER RNA - Abstract
Background: Embryo retention in the Fallopian tube (FT) is thought to lead to ectopic pregnancy (EP), a considerable cause of morbidity. In mice, genetic/pharmacological silencing of cannabinoid receptor Cnr1, encoding CB1, causes retention of embryos in the oviduct. The role of the endocannabinoids in tubal implantation in humans is not known. Methods and Findings: Timed FT biopsies (n = 18) were collected from women undergoing gynecological procedures for benign conditions. Endometrial biopsies and whole blood were collected from women undergoing surgery for EP (n = 11); management of miscarriage (n = 6), and termination of pregnancy (n = 8). Using RT-PCR and immunohistochemistry, CB1 mRNA and protein expression levels/patterns were examined in FT and endometrial biopsies. The distribution of two polymorphisms of CNR1 was examined by TaqMan analysis of genomic DNA from the whole blood samples. In normal FT, CB1 mRNA was higher in luteal compared to follicular-phase (p<0.05). CB1 protein was located in smooth muscle of the wall and of endothelial vessels, and luminal epithelium of FT. In FT from women with EP, CB1 mRNA expression was low. CB1 mRNA expression was also significantly lower (p<0.05) in endometrium of women with EP compared to intrauterine pregnancies (IUP). Although of 1359G/A (rs1049353) polymorphisms of CNR1 gene suggests differential distribution of genotypes between the small, available cohorts of women with EP and those with IUP, results were not statistically significant. Conclusions: CB1 mRNA shows temporal variation in expression in human FT, likely regulated by progesterone. CB1 mRNA is expressed in low levels in both the FT and endometrium of women with EP. We propose that aberrant endocannabinoidsignaling in human FT leads to EP. Furthermore, our finding of reduced mRNA expression along with a possible association between polymorphism genotypes of the CNR1 gene and EP, suggests a possible genetic predisposition to EP that warrants replication in a larger sample pool. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
50. Intercellular adhesion molecule-1 expression in human endometrium: implications for long term progestin only contraception.
- Author
-
Schatz, Frederick, Krikun, Graciela, Baergen, Rebecca N., Critchley, Hilary O. D., Kuczynski, Edward, and Lockwood, Charles J.
- Subjects
- *
ENDOMETRIUM , *CELL adhesion molecules , *CONTRACEPTION , *PROGESTERONE , *LEVONORGESTREL intrauterine contraceptives , *NORGESTREL - Abstract
Background: Neutrophils infiltrate the endometrium pre-menstrually and after long-term progestin only-contraceptive (LTPOC) treatment. Trafficking of neutrophils involves endothelial cell-expressed intercellular adhesion molecule (ICAM-1). Previous studies observed that ICAM-1 was immunolocalized to the endothelium of endometrial specimens across the menstrual cycle, but disagreed as to whether extra-endothelial cell types express ICAM-1 and whether ICAM-1 expression varies across the menstrual cycle. Methods: Endometrial biopsies were obtained from women across the menstrual cycle and from those on LTPOC treatment (either Mirena or Norplant). The biopsies were formalin-fixed and paraffin-embedded with subsequent immunohistochemical staining for ICAM-1. Results: The current study found prominent ICAM-1 staining in the endometrial endothelium that was of equivalent intensity in different blood vessel types irrespective of the steroidal or inflammatory endometrial milieu across the menstrual cycle and during LTPOC therapy. Unlike the endothelial cells, the glands were negative and the stromal cells were weakly positive for ICAM immunostaining. Conclusion: The results of the current study suggest that altered expression of ICAM-1 by endothelial cells does not account for the influx of neutrophils into the premenstrual and LTPOC-derived endometrium. Such neutrophil infiltration may depend on altered expression of neutrophil chemoattractants. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.